See more : UNIVA Oak Holdings Limited (3113.T) Income Statement Analysis – Financial Results
Complete financial analysis of Bruker Corporation (BRKR) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bruker Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
- Gévelot SA (ALGEV.PA) Income Statement Analysis – Financial Results
- Caterpillar Inc. (CAT1.DE) Income Statement Analysis – Financial Results
- Maan Aluminium Limited (MAANALU.NS) Income Statement Analysis – Financial Results
- Takung Art Co., Ltd. (TKAT) Income Statement Analysis – Financial Results
- Sino Energy International Holdings Group Limited (1096.HK) Income Statement Analysis – Financial Results
Bruker Corporation (BRKR)
About Bruker Corporation
Bruker Corporation develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States and internationally. The company operates through three segments: Bruker Scientific Instruments (BSI) Life Science, BSI NANO, and Bruker Energy & Supercon Technologies. It offers life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper rapid pathogen identification platform and related test kits, DNA test strips, and fluorescence-based polymerase chain reaction technology; genotype and fluorotype molecular diagnostics kits; research, analytical, and process analysis instruments and solutions; SARS-CoV 2 testing for the diagnosis of COVID-19 infection; and Fluorotyper-SARS-CoV 2 plus kits. It also provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. Bruker Corporation has a collaboration with Newomics Inc. on a LC-MS platform for drug discovery. The company was incorporated in 1991 and is headquartered in Billerica, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.96B | 2.53B | 2.42B | 1.99B | 2.07B | 1.90B | 1.77B | 1.61B | 1.62B | 1.81B | 1.84B | 1.79B | 1.65B | 1.30B | 1.11B | 1.11B | 547.58M | 435.83M | 297.57M | 284.42M | 260.68M | 116.37M | 92.69M | 76.60M | 64.69M | 42.21M |
| Cost of Revenue | 1.45B | 1.23B | 1.21B | 1.05B | 1.08B | 995.60M | 952.90M | 868.80M | 915.20M | 1.05B | 1.03B | 960.00M | 899.20M | 698.90M | 595.90M | 602.10M | 294.44M | 236.50M | 171.76M | 165.94M | 144.83M | 55.87M | 43.59M | 35.59M | 28.13M | 0.00 |
| Gross Profit | 1.51B | 1.31B | 1.21B | 939.80M | 995.30M | 900.00M | 813.00M | 742.50M | 708.60M | 763.30M | 805.20M | 831.40M | 752.50M | 606.00M | 518.60M | 505.00M | 253.14M | 199.33M | 125.81M | 118.48M | 115.85M | 60.50M | 49.10M | 41.02M | 36.56M | 42.21M |
| Gross Profit Ratio | 51.05% | 51.59% | 50.03% | 47.29% | 48.02% | 47.48% | 46.04% | 46.08% | 43.64% | 42.20% | 43.78% | 46.41% | 45.56% | 46.44% | 46.53% | 45.61% | 46.23% | 45.74% | 42.28% | 41.66% | 44.44% | 51.99% | 52.97% | 53.54% | 56.51% | 100.00% |
| Research & Development | 294.80M | 235.90M | 220.80M | 198.00M | 187.70M | 173.40M | 162.70M | 149.00M | 145.70M | 174.20M | 190.50M | 195.30M | 177.20M | 141.40M | 126.40M | 133.80M | 58.47M | 49.96M | 41.36M | 43.22M | 38.03M | 20.73M | 18.47M | 20.03M | 15.14M | 0.00 |
| General & Administrative | 730.10M | 610.80M | 564.50M | 477.80M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 406.60M | 303.10M | 69.50M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
| Selling & Marketing | 0.00 | -3.40M | -3.30M | -9.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.00M | -5.80M | 185.80M | 183.80M | 105.98M | 84.01M | 51.44M | 55.98M | 60.42M | 26.81M | 21.71M | 0.00 | 0.00 | 0.00 |
| SG&A | 730.10M | 607.40M | 561.20M | 468.60M | 500.20M | 444.70M | 415.90M | 390.50M | 392.20M | 451.00M | 437.90M | 442.40M | 403.60M | 297.30M | 255.30M | 254.50M | 140.04M | 112.99M | 73.81M | 76.38M | 77.76M | 33.82M | 27.72M | 20.25M | 14.76M | 0.00 |
| Other Expenses | 52.20M | -29.70M | -14.30M | -24.90M | -6.50M | -19.50M | -19.70M | -25.80M | -20.40M | -21.20M | -28.60M | -13.90M | 13.10M | 5.80M | 200.00K | 8.50M | 4.66M | 5.72M | 0.00 | 0.00 | 9.75M | 202.00K | -356.00K | 0.00 | 3.49M | 42.37M |
| Operating Expenses | 1.08B | 843.30M | 782.00M | 666.60M | 687.90M | 618.10M | 578.60M | 539.50M | 537.90M | 625.20M | 628.40M | 637.70M | 596.90M | 450.30M | 255.30M | 388.30M | 198.51M | 162.95M | 115.17M | 119.59M | 125.53M | 54.75M | 45.83M | 40.28M | 33.38M | 42.37M |
| Cost & Expenses | 2.53B | 2.07B | 1.99B | 1.71B | 1.77B | 1.61B | 1.53B | 1.41B | 1.45B | 1.67B | 1.66B | 1.60B | 1.50B | 1.15B | 851.20M | 990.40M | 492.95M | 399.45M | 286.93M | 285.53M | 270.36M | 110.62M | 89.42M | 75.87M | 61.51M | 42.37M |
| Interest Income | 11.20M | 4.10M | 900.00K | 3.20M | 1.30M | 1.20M | 800.00K | 300.00K | 1.20M | 800.00K | 1.00M | 900.00K | 1.00M | 900.00K | 1.00M | 4.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 16.40M | 16.10M | 14.30M | 14.40M | 16.00M | 12.60M | 15.40M | 13.20M | 13.00M | 13.30M | 13.40M | 14.30M | 7.30M | 5.60M | 7.50M | 40.50M | 11.84M | 3.96M | 0.00 | 3.85M | 6.36M | 20.15M | 0.00 | 0.00 | 1.35M | 0.00 |
| Depreciation & Amortization | 114.90M | 88.80M | 89.20M | 80.50M | 75.60M | 64.90M | 63.90M | 54.30M | 53.30M | 59.70M | 61.30M | 59.10M | 3.00M | 5.80M | 29.70M | 29.90M | 12.63M | 13.29M | 8.61M | 9.79M | 16.87M | 8.20M | 6.04M | 4.15M | 3.49M | 0.00 |
| EBITDA | 599.00M | 545.30M | 497.10M | 320.70M | 380.00M | 340.10M | 299.50M | 262.10M | 235.90M | 215.60M | 239.10M | 211.70M | 205.70M | 155.70M | 166.30M | 134.80M | 63.07M | 49.87M | 19.25M | 8.68M | 697.00K | 17.47M | 10.30M | 4.88M | 6.66M | -161.00K |
| EBITDA Ratio | 20.21% | 21.75% | 21.37% | 17.79% | 18.48% | 18.29% | 16.89% | 15.97% | 14.08% | 11.57% | 12.94% | 12.14% | 9.60% | 12.38% | 35.67% | 14.75% | 13.29% | 11.85% | 6.47% | 3.05% | 5.91% | 20.80% | 9.68% | 6.64% | 10.93% | -0.38% |
| Operating Income | 436.90M | 432.70M | 413.30M | 248.30M | 300.90M | 262.40M | 214.70M | 177.20M | 145.70M | 105.40M | 148.20M | 156.00M | 155.60M | 155.70M | 136.70M | 108.20M | 49.97M | 30.66M | 10.64M | -1.12M | -9.68M | 5.75M | 3.27M | 734.00K | 3.18M | -161.00K |
| Operating Income Ratio | 14.74% | 17.10% | 17.09% | 12.49% | 14.52% | 13.84% | 12.16% | 11.00% | 8.97% | 5.83% | 8.06% | 8.71% | 9.42% | 11.93% | 12.27% | 9.77% | 9.13% | 7.04% | 3.57% | -0.39% | -3.71% | 4.94% | 3.53% | 0.96% | 4.91% | -0.38% |
| Total Other Income/Expenses | 107.30M | -18.80M | -19.70M | -22.50M | -20.50M | -17.70M | -21.70M | -4.20M | -17.70M | -4.10M | -23.60M | -17.70M | -10.10M | -5.60M | -7.60M | -15.00M | -89.09M | 3.76M | -780.00K | -3.78M | 1.85M | -9.88M | 2.73M | 1.59M | -1.32M | 161.00K |
| Income Before Tax | 544.20M | 413.90M | 393.60M | 225.80M | 280.40M | 244.70M | 197.80M | 177.60M | 128.00M | 101.30M | 124.60M | 138.30M | 145.50M | 150.10M | 129.10M | 93.20M | 48.61M | 34.42M | 11.95M | -4.90M | -7.83M | -4.14M | 6.01M | 2.32M | 1.86M | 0.00 |
| Income Before Tax Ratio | 18.36% | 16.36% | 16.28% | 11.36% | 13.53% | 12.91% | 11.20% | 11.02% | 7.88% | 5.60% | 6.77% | 7.72% | 8.81% | 11.50% | 11.58% | 8.42% | 8.88% | 7.90% | 4.02% | -1.72% | -3.00% | -3.56% | 6.48% | 3.03% | 2.88% | 0.00% |
| Income Tax Expense | 117.70M | 116.40M | 113.00M | 64.40M | 82.40M | 63.70M | 117.50M | 23.10M | 23.10M | 41.70M | 42.80M | 60.10M | 51.50M | 53.30M | 48.10M | 28.00M | 16.78M | 15.93M | 8.26M | 2.87M | 9.72M | 2.06M | 2.37M | 254.00K | 986.89K | 0.00 |
| Net Income | 427.20M | 296.60M | 277.10M | 157.80M | 197.20M | 179.70M | 78.60M | 153.60M | 101.60M | 56.70M | 80.10M | 77.50M | 92.30M | 95.40M | 81.20M | 64.90M | 31.53M | 18.48M | 3.65M | -7.83M | -17.55M | -6.20M | 3.64M | 2.25M | 1.25M | 0.00 |
| Net Income Ratio | 14.41% | 11.72% | 11.46% | 7.94% | 9.51% | 9.48% | 4.45% | 9.53% | 6.26% | 3.13% | 4.35% | 4.33% | 5.59% | 7.31% | 7.29% | 5.86% | 5.76% | 4.24% | 1.23% | -2.75% | -6.73% | -5.33% | 3.92% | 2.94% | 1.93% | 0.00% |
| EPS | 2.92 | 2.00 | 1.83 | 1.03 | 1.27 | 1.15 | 0.50 | 0.95 | 0.60 | 0.34 | 0.48 | 0.47 | 0.56 | 0.58 | 0.50 | 0.40 | 0.61 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
| EPS Diluted | 2.90 | 1.99 | 1.81 | 1.02 | 1.26 | 1.14 | 0.49 | 0.95 | 0.60 | 0.33 | 0.48 | 0.46 | 0.55 | 0.58 | 0.49 | 0.39 | 0.60 | 0.18 | 0.10 | -0.08 | -0.17 | -0.12 | -0.05 | 0.04 | 0.03 | 0.00 |
| Weighted Avg Shares Out | 146.40M | 148.60M | 151.40M | 153.40M | 155.20M | 156.20M | 158.10M | 161.40M | 168.20M | 167.80M | 166.50M | 166.00M | 165.40M | 164.40M | 163.50M | 162.70M | 161.20M | 101.51M | 100.82M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
| Weighted Avg Shares Out (Dil) | 147.20M | 149.40M | 152.90M | 154.60M | 156.60M | 157.20M | 159.10M | 162.20M | 169.10M | 169.50M | 168.50M | 167.40M | 166.90M | 165.70M | 164.90M | 165.60M | 164.30M | 102.56M | 101.13M | 96.38M | 103.26M | 52.60M | 54.06M | 56.25M | 45.50M | 45.50M |
Bruker Corporation to Present at Upcoming Investor Conferences
Bruker (BRKR) Rolls Out the First 1.2 GHz NMR System in Asia
Bruker (BRKR) Reliance on International Sales: What Investors Need to Know
Bruker Corporation (BRKR) Q2 2024 Earnings Call Transcript
Bruker (BRKR) Partners With NovAliX to Boost Drug Discovery
Bruker (BRKR) Q2 Earnings Meet Mark, '24 Revenue Outlook Raised
Compared to Estimates, Bruker (BRKR) Q2 Earnings: A Look at Key Metrics
Is the Options Market Predicting a Spike in Bruker (BRKR) Stock?
Bruker (BRKR) Q2 Earnings Meet Estimates
Bruker Reports Second Quarter 2024 Financial Results
Source: https://incomestatements.info
Category: Stock Reports